125 related articles for article (PubMed ID: 29740874)
21. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
Cho YY; Cho SI
Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
[TBL] [Abstract][Full Text] [Related]
22. Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women.
Topyildiz F; Kiyici S; Gul Z; Sigirli D; Guclu M; Kisakol G; Cavun S
J Diabetes Res; 2016; 2016():1309502. PubMed ID: 26998491
[TBL] [Abstract][Full Text] [Related]
23. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
[TBL] [Abstract][Full Text] [Related]
24. Evaluation, efficacy and tolerability of GlucoNovax tablet in type 2 diabetic patients.
Ali Z; Daniyal M; S I I; Usmanghani K; Naveed S
Pak J Pharm Sci; 2016 Jul; 29(4 Suppl):1443-9. PubMed ID: 27592478
[TBL] [Abstract][Full Text] [Related]
25. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).
Cvetković RS; Plosker GL
Drugs; 2007; 67(6):935-54. PubMed ID: 17428109
[TBL] [Abstract][Full Text] [Related]
26. Clinical evaluation of combined therapy for type 2 diabetes.
Rodríguez A; Ciprés L; Tofé S; Polavieja P; Reviriego J
Curr Med Res Opin; 2010 May; 26(5):1171-83. PubMed ID: 20297952
[TBL] [Abstract][Full Text] [Related]
27. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
[TBL] [Abstract][Full Text] [Related]
28. Gliquidone versus metformin: differential effects on aorta in streptozotocin induced diabetic rats.
Tan Z; Xu Z; Gui Q; Wu W; Yang Y
Chin Med J (Engl); 2014; 127(7):1298-303. PubMed ID: 24709184
[TBL] [Abstract][Full Text] [Related]
29. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
30. Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial.
Out M; Miedema I; Jager-Wittenaar H; van der Schans C; Krijnen W; Lehert P; Stehouwer C; Kooy A
Diabetes Obes Metab; 2018 Jan; 20(1):219-223. PubMed ID: 28681986
[TBL] [Abstract][Full Text] [Related]
31. The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules.
Lule KO; Akarsu E; Sayiner ZA; Lule NO; Balci SO; Demirel C; Bozdag Z; Korkmaz M; Yilmaz I
Inflammopharmacology; 2022 Feb; 30(1):243-250. PubMed ID: 35072848
[TBL] [Abstract][Full Text] [Related]
32. Exenatide.
Keating GM
Drugs; 2005; 65(12):1681-92; discussion 1693-5. PubMed ID: 16060703
[TBL] [Abstract][Full Text] [Related]
33. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
34. Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
Ma RL; Deng Y; Wang YF; Zhu SY; Ding XS; Sun AJ
Chin Med J (Engl); 2021 Nov; 134(23):2882-2889. PubMed ID: 34732660
[TBL] [Abstract][Full Text] [Related]
35. Regulation of Glycemia in the Recovery Phase After Stroke Counteracts the Detrimental Effect of Obesity-Induced Type 2 Diabetes on Neurological Recovery.
Augestad IL; Pintana H; Larsson M; Krizhanovskii C; Nyström T; Klein T; Darsalia V; Patrone C
Diabetes; 2020 Sep; 69(9):1961-1973. PubMed ID: 32540876
[TBL] [Abstract][Full Text] [Related]
36. Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial.
Kang C; Qiao Q; Tong Q; Bai Q; Huang C; Fan R; Wang H; Kaliannan K; Wang J; Xu J
Sci Rep; 2021 Oct; 11(1):20062. PubMed ID: 34625598
[TBL] [Abstract][Full Text] [Related]
37. Effect of Metformin on Testosterone Levels in Male Patients With Type 2 Diabetes Mellitus Treated With Insulin.
Cai T; Hu Y; Ding B; Yan R; Liu B; Cai L; Jing T; Jiang L; Xie X; Wang Y; Wang H; Zhou Y; He K; Xu L; Chen L; Cheng C; Ma J
Front Endocrinol (Lausanne); 2021; 12():813067. PubMed ID: 35002984
[TBL] [Abstract][Full Text] [Related]
38. Management of the overweight patient with Type 2 diabetes.
Peter P; Kumar S
Diabet Med; 2003 Sep; 20 Suppl 4():10-3. PubMed ID: 12940860
[No Abstract] [Full Text] [Related]
39. The Impact of Testosterone on Metformin Action on Hypothalamic-Pituitary-Thyroid Axis Activity in Men: A Pilot Study.
Krysiak R; Szkróbka W; Okopień B
J Clin Pharmacol; 2020 Feb; 60(2):164-171. PubMed ID: 31389032
[TBL] [Abstract][Full Text] [Related]
40. Metformin reduces serum CA199 levels in type 2 diabetes Chinese patients with time-effect and gender difference.
Zhang D; Hou W; Liu F; Yin J; Lu W; Li M; Zheng T; Lu F; Bao Y; Jia W
Diabetes Technol Ther; 2015 Feb; 17(2):72-9. PubMed ID: 25548963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
